Pros | Among most bought funds within the category. Beats FD returns for both 3Y & 5Y duration. | 5Y returns in the top 25% of the category. 3Y returns in the top 25% of the category. Among most bought funds within the category. | ||
Cons | - | - |
INDMoney rank | 4/8 | 2/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 7 Years | 7 Years | ||
Fund Size | 3144 Cr | 6437 Cr | ||
Min Investment | SIP ₹100 Lumpsum ₹100 | SIP ₹100 Lumpsum ₹5000 | ||
Expense Ratio | 0.56% | 1.03% | ||
Exit Load | 0.5% | 1% | ||
Benchmark Index | BSE Healthcare TR INR | BSE Healthcare TR INR |
No of Holdings | 32 | 44 | ||
Top 5 Holdings | Cipla Ltd (8.55%) Sun Pharmaceuticals Industries Ltd (8.26%) Ipca Laboratories Ltd (7.39%) Cohance Lifesciences Ltd (7.11%) Laurus Labs Ltd (6.73%) | Sun Pharmaceuticals Industries Ltd (11.88%) Dr Reddy's Laboratories Ltd (9.42%) Divi's Laboratories Ltd (8.5%) Aurobindo Pharma Ltd (7.62%) Cipla Ltd (6.61%) | ||
No of Sectors | 2 | 3 | ||
Top 3 Sectors | Health (98.45%) Financial Services (1.55%) | Health (97.59%) Basic Materials (1.21%) Financial Services (1.2%) | ||
Equity % | 98.69% | 97.1% | ||
Debt % | - | - | ||
P/E | - | - | ||
P/B | - | - | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | 0.9% | -0.66% | ||
3-Month Return | 1.2% | 0.84% | ||
6-Month Return | 4.78% | 4.17% | ||
1-Year Return | -3.4% | 4.02% | ||
3-Year Return | 22.39% | 27.76% | ||
5-Year Return | 17.87% | 19.68% |
Sharpe | - | - | ||
Alpha | - | - | ||
Beta | - | - | ||
Standard Deviation | - | - | ||
Information Ratio | - | - |
Description | DSP Healthcare Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Chirag Dagli | Dharmesh Kakkad,Sharmila D’mello |